# Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

4	Kosuke Yoshihara	MD,	$PhD^{1}$ ,	Tsukasa	Baba MD,	PhD <sup>2</sup> ,	Muneaki	Shimada	MD,	PhD <sup>3</sup> ,	Koji
---	------------------	-----	-------------	---------	----------	--------------------	---------	---------	-----	--------------------	------

- 5 Nishino MD, PhD<sup>1</sup>, Masayuki Sekine MD, PhD<sup>1</sup>, Shiro Takamatsu MD<sup>4</sup>, Noriomi Matsumura
- 6 MD, PhD<sup>5</sup>, Hiroshi Yoshida MD, PhD<sup>6,13</sup>, Hiroaki Kajiyama MD, PhD<sup>7</sup>, Tatsuo Kagimura PhD<sup>8</sup>,
- 7 Katsutoshi Oda MD, PhD<sup>9</sup>, Yuko Sasajima MD, PhD<sup>10</sup>, Aikou Okamoto MD, PhD<sup>11</sup>, Toru
- 8 Sugiyama MD, PhD<sup>12</sup>, Takayuki Enomoto MD, PhD<sup>1,14</sup>
- 9
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical
   and Dental Sciences, Niigata, Japan
- 12 2. Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan
- 13 3. Department of Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
- 14 4. Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University,
- 15 Kyoto, Japan
- 16 5. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka,
  17 Japan
- 18 6. Department of Obstetrics and Gynecology, Yokohama Municipal Citizen's Hospital,19 Yokohama, Japan
- 20 7. Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine,
  21 Nagoya, Japan
- 22 8. Translational Research Center for Medical Innovation, Kobe, Japan
- 23 9. Division of Integrative Genomics, University of Tokyo, Tokyo, Japan

24	10.	Department of Pathology, Teikyo University Hospital, Tokyo, Japan
25	11.	Department of Obstetrics and Gynecology, The Jikei University School of Medicine,
26		Tokyo, Japan
27	12.	Department of Obstetrics and Gynecology, St. Mary's Hospital, Fukuoka, Japan
28	13.	Department of Obstetrics and Gynecology, Tokai University Graduate School of
29		Medicine, Isehara, Japan (present)
30	14.	Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
31		
32	Corre	esponding authors: Takayuki Enomoto
33	Takay	zuki Enomoto MD, PhD
34	Niiga	ta University Graduate School of Medical and Dental Sciences
35	E-ma	il: enomoto@med.niigata-u.ac.jp
36	Phone	e: +81-25-227-2320
37	Fax: -	+81-25-227-0789
38		
39	Keyw	vords: Ovarian cancer, Homologous recombination deficiency, Target-gene sequencing,
40	HITO	MI study
41		
42	Manu	ascript word count: 3759 words
43	Numł	per of Figures: 6
44	Numł	per of Tables: 2
45	Numł	per of Supporting Information: 2

#### 46 Abstract

47 The Cancer Genome Atlas has clarified that about 50% of high-grade serous ovarian cancer shows homologous recombination deficiency (HRD). However, the frequency of HRD in 48 49 Japanese patients with ovarian cancer remains unclear. The aim of JGOG3025 study 50 (NCT03159572) is to identify the frequency of HRD in Japanese patients with ovarian cancer. The JGOG3025 study is a multicenter collaborative prospective observational study involving 65 51 52 study sites throughout Japan. We recruited 996 patients who were clinically diagnosed with 53 ovarian cancer before surgery from March 2017 to March 2019, and 701 patients were eligible 54 for JGOG3025 criteria. We used frozen tumor tissues to extract DNA and performed targeted 55 sequencing for 51 genes most of which are HR-associated genes in 701 ovarian cancers (298 56 high-grade serous, 189 clear cell, 135 endometrioid, 12 mucinous, 3 low-grade serous, and 64 57 others). HRD was defined as positive when at least one HR-associated gene was mutated. The 58 frequencies of HRD and tumor BRCA1/2 mutation were 45.2% (317/701) and 18.5% (130/701) 59 in the full analysis set (FAS), respectively. Next, we performed multivariate Cox proportional 60 hazards regression analysis for progression-free survival (PFS) and overall survival (OS). 61 Advanced-stage ovarian cancer patients with HRD had an adjusted hazard ratio of 0.72 (95%CI, 62 (0.55-0.93) and (0.58) (95%CI, (0.39-0.87)) for PFS and OS compared to those without HRD (p = 63 0.013 and 0.009). Our study demonstrated that mutations in HR-associated genes might be 64 associated with their prognosis. Further study will be needed to investigate prognostic impact of 65 each HR-associated gene in ovarian cancer.

## 66 Abbreviations

- 67 aHR: adjusted hazard ratio
- 68 CI: Confidence Interval
- 69 FAS: Full analysis set
- 70 FIGO: International Federation of Gynecology and Obstetrics
- 71 GI: Genomic Instability
- 72 HR: homologous recombination
- 73 HRD: homologous recombination deficiency
- 74 JGOG: Japanese Gynecologic Oncology Group
- 75 MSI: Microsatellite instability
- 76 NAC: Neoadjuvant chemotherapy
- 77 OS: Overall survival
- 78 PARP: poly (ADP-ribose) polymerase
- 79 PFS: Progression free survival
- 80 PS: Performance status
- 81 SNV: Single nucleotide variant
- 82 TCGA: The Cancer Genome Atlas
- 83 ToMMo: Tohoku Medical Megabank organization
- 84 VAF: variant allele frequency

85

#### 87 **1. Introduction**

Homologous recombination deficiency (HRD) has attracted attention as a new molecular 88 biomarker in gynecologic oncology field<sup>1</sup>. Homologous recombination (HR) repair is one of the 89 90 repair mechanisms for DNA double-strand breaks, in which the ends of double-strand breaks are precisely repaired<sup>2</sup>. In humans, several genes including BRCA1/2 and RAD51 are involved in 91 92 HR repair, and genomic alterations in these HR-associated genes result in HRD. In HRD cells, 93 DNA repair mechanisms other than HR repair are important, especially poly (ADP-ribose) 94 polymerase (PARP) is focused on a new therapeutic target. PARP inhibition in HRD cells leads to genomic instability and cell death (synthetic lethality)<sup>3</sup>. At present, two PARP inhibitors 95 96 (olaparib and niraparib) have become clinically available for ovarian cancer in Japan. 97 Interestingly, two phase III trials have demonstrated that niraparib significantly prolonged 98 progression-free survival (PFS) in not only patients with BRCA1/2 mutations but also those with 99 HRD compared to placebo<sup>4, 5</sup>. PAOLA-1 regimen (olaparib + bevacizumab) also provides a significant PFS benefit in patients with HRD<sup>6</sup>. Thus, HRD status is an important factor in the 100 101 treatment of ovarian cancer.

102 The Cancer Genome Atlas (TCGA), a national cancer genome project of the United States, found 103 that about half of high-grade serous ovarian cancers have genomic or epigenomic alterations in 104 the HR-associated pathway such as *BRCA1/2* mutations, *BRCA1* methylation, *CDK12* mutations, and *RAD51C* promoter methylation<sup>7, 8</sup>. However, the frequency of HR-associated mutations in 105 106 ovarian cancer in Japan remains unclear, especially in non-serous histologic type. Because there 107 are differences in the distribution of histologic types in ovarian cancer between the United States 108 and Japan, the results of TCGA cannot be directly applied to Japan. In addition, clinical 109 significance of HRD remains unclear compared to that of germline BRCA1/2 mutation.

110 Therefore, it is an urgent issue to investigate the frequency and clinical significance of HRD in111 Japanese patients with ovarian cancer.

So, on 2017, we started JGOG3025 trial, which was a multicenter collaborative prospective observational study, to clarify the frequency of HRD in Japanese patients with ovarian cancer. We defined the presence of at least one HR-associated gene mutation as HRD in this study. We closed enrollment of the participants at the end of March 2019, and fixed data after 30 months of follow-up. We report the results of final analysis in the JGOG3025 trial.

117

#### 118 **2.** Materials and Methods

#### 119 **2.1 Patients and study design**

120 A multicenter collaborative prospective observational study (ClinicalTrials.gov, NCT03159572; 121 UMIN 000026303) was conducted in Japan between January 2017 and September 2021. We 122 enrolled the participants for 27 months between January 2017 and March 2019 and the follow-up 123 period was 30 months after the end of enrollment. The target sample size was 700. Study schema 124 is shown in Figure 1. Patients diagnosed with ovarian cancer clinically were enrolled in 65 125 Japanese Gynecologic Oncology Group (JGOG) institutions throughout Japan (Table S1). After 126 written informed consent for HRD test and biobanking, we obtained tumor tissue samples during 127 surgery. Tumor tissue samples were sent to JGOG-Tohoku Medical Megabank organization 128 (ToMMo) Biobank under controlled temperature. We performed HRD test after the end of 129 enrollment. When patients had the information of germline BRCA1/2 mutation and allowed us to 130 use this information in this study, germline BRCA1/2 mutation status was also submitted to data 131 center. Treatment selection was basically performed according to the Japan Society of 132 Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and

primary peritoneal cancer<sup>9, 10</sup>. All evaluations were scheduled according to the clinical practice
standards of each institution.

We collected data including patient characteristics, clinicopathological data, clinical outcome,
and adverse events. Clinical outcome was updated prospectively every 6 months on the
electronic data capture system.

The study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. Approval from the institutional review board of each participating JGOG institution was obtained prior to initiation of the study. All patients provided written informed consent.

142

#### 143 **2.2 Study population**

144 The inclusion criteria are as follows: Patients who can approve informed consent and sign it; 145 Patients who show their will to participate in this study and can sign the informed consent forms 146 by themselves; Patients who are clinically diagnosed as ovarian cancer and can provide written 147 informed consent before the surgery; Patients who are 20 years old and over at the enrollment; 148 Patients with ECOG Performance status (PS) 0-2; Patients who can provide tumor tissue 149 specimens. Ascites cytology and cell block specimens are not considered tumor tissue specimens. 150 For patients to be treated with Neoadjuvant Chemotherapy (NAC), a tumor biopsy should be 151 performed prior to NAC to make a pathologic diagnosis and to obtain a tumor tissue specimen. 152 Patients are excluded based on the following criteria: Patients with other clinically active 153 malignancy (except breast cancer) that have been treated within 5 years (excluding basal cell 154 carcinoma and squamous cell carcinoma of the skin, and carcinoma in situ or intramucosal

155 carcinoma which are curable with local treatment); the principal investigator judges that 156 enrollment of the patient in the study is inappropriate.

157

#### 158 2.3 Study outcomes

The primary outcome of JGOG3025 trial is to identify the HRD frequency in Japanese patients with ovarian cancer including fallopian tube cancer and primary peritoneal cancer. The secondary outcome is to assess associations between PFS and HRD in ovarian cancer and between PFS and germline BRCA1/2 mutation in ovarian cancer. PFS was defined as the time from registration in the trial to disease progression or death from any cause.

164

#### 165 **2.4 Definition of HRD**

We performed target-gene sequencing of 51 genes by using DNA extracted from cancer tissues.
A list of genes is shown in Table S2. Five genes (*ARID1A, KRAS, PIK3CA, PTEN*, and *TP53*)
were included as molecular diagnostic markers in ovarian cancer, and 29 genes were categorized
as HR-associated genes. We used QIAseq Targeted DNA Custom Panel (CDHS-16649Z-2451,
Qiagen) and conducted 150bp paired-end sequencing on the Illumina NextSeq sequencer. Single
nucleotide variant (SNV) or short InDel was detected by smCounter2 (Qiagen)<sup>11</sup>. Variant
annotation was performed using ANOVAR version 20190408<sup>12</sup>.

To make a mutation list, we generated MAF file using maftools<sup>13</sup> and filtered as follow: variants with variant allele frequency(VAF) less than 5% were excluded; variants classified as Nonsense, Frame Shift InDel, Nonstop, Traslation Start Site, Missense, Splice Site were included; variants with VAF more than 1% in gnomAD<sup>14</sup>, 1000 Genomes Project<sup>15</sup>, ExAC<sup>16</sup>, ESP6500<sup>17</sup>, or 14K Japanese custom reference from jMorp<sup>18</sup> were excluded; variants interpreted as pathogenic or

178 likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) or InterVar<sup>19</sup> were 179 included; Based on dbsnpf35a or dbscsnv11, Missense variants with deleterious 2 predictions or 180 Splice variants with deleterious > 1 prediction were included; variants which are not found in 181 both  $COSMIC^{20}$  and  $ICGC^{21}$  were excluded.

As for HRD, we defined case harboring at least one mutation of HR-associated genes as HRD and case without any HR-associated gene mutation as non-HRD. Because Microsatellite Instability (MSI)-high or POLE mutated ovarian cancers showing very high tumor mutational burden led to passenger mutation of HR-associated genes, cases with both HR associated gene mutations and MSI-high or POLE mutations were determined as HRD negative.

187

#### 188 **2.5 Central pathological review**

To confirm the histological diagnosis, central pathological review was performed by three pathologists assigned by the Japanese Gynecologic Oncology Group using hematoxylin and eosin slide specimens from tumor tissues. The central histological evaluation and diagnosis of ovarian cancer was based on the WHO classification of tumors of female reproductive organs.

193

#### 194 **2.6 Statistical analysis**

Descriptive statistics were used for clinicopathological characteristics, with n (%) for categorical variable. The full analysis set (FAS) consisted of all ovarian cancer patients with target-gene sequencing data. The frequency of HRD was calculated, together with 95% CIs, for all patients, and was stratified by FIGO stage and histologic types. Cox proportional hazard model analysis was performed to investigate an association of HRD or germline *BRCA1/2* status with PFS or OS after adjustment for age, stage, histologic type, surgery, NAC, and adjuvant chemotherapy. All

- statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA) or
  R version 4.1.1 (https://www.R-project.org/.).
- 203
- 204 **3. Results**

### 205 **3.1 Patient characteristics**

The study was conducted from June 2015 to November 2019. The enrollment period was initially planned for 2 years but was extended to 2 years 3 months to reach the sample size required. The patient disposition is shown in Figure 2. A total of 996 patients who were clinically diagnosed with ovarian cancer were enrolled, but 295 patients were excluded from the full analysis set according to the eligibility criteria. A total of 701 patients were included in the final analysis. Patient characteristics are shown in Table 1. Patients in the full analysis set had a mean age of 58.4 years. Of 701 patients, 47.4% were stage I/II and 51.6% were stage III/IV.

213

#### 214 **3.2 Primary outcome**

The frequency of HRD in Japanese patients with ovarian cancer was 45.2% (317/701) (Figure 1). The mutation rates of tumor *BRCA1* and *BRCA2* were 9.8%, 7.7%, respectively. Seven patients (1.0%) had both germline *BRCA1* and *BRCA2* mutations. On the other hand, the mutation rate of HR-associated genes except *BRCA1/2* was 26.7%.

219

#### 220 **3.3 Secondary outcomes**

First, we performed Cox proportional hazard model analysis after adjustment for age, stage,histologic type, surgery, NAC, and adjuvant chemotherapy. There was no significant difference

in PFS between HRD and non-HRD groups (adjusted hazard ratio (aHR), 0.84; 95% confidence
interval (CI), 0.66-1.06; p = 0.14).

Next, we stratified ovarian cancers by FIGO stage. Although there was no significant difference in PFS between stage I/II HRD and non-HRD subgroups (aHR, 1.35; 95%CI, 0.82-2.24; p = 0.24), PFS in stage III/IV HRD subgroup was significantly longer than that in non-HRD subgroup (aHR, 0.72; 95%CI, 0.55-0.93; p = 0.013) (Figure 4). In addition, OS in stage III/IV HRD subgroup was also significantly longer than that in non-HRD subgroup (aHR, 0.58; 95%CI, 0.39-0.87; p = 0.009) (Figure 5).

The frequency of HRD by histologic type was shown in Table 2. In patients with high-grade serous carcinoma, the frequencies of both HRD and tumor *BRCA1/2* mutations were relatively higher than those of other histologic types. Although the frequency of HRD in clear-cell type was also relatively high, tumor *BRCA1/2* mutation rate was lower than that of high-grade serous carcinoma.

236 Finally, we focused on germline BRCA1/2 mutation status in ovarian cancer. We collected 237 germline BRCA1/2 information from 112 participants. Of them, germline BRCA1/2 mutations 238 were positive in 21 participants. 18 of which were identified in the corresponding tumors in this 239 study cohort. There was no significant difference in PFS between PFS and germline BRCA1/2 in 240 stage I/II ovarian cancer because only three participants harbor germline BRCA1/2 mutation 241 (aHR, 1.12; 95%CI, 0.08-15.67; p = 0.93). On the other hand, germline *BRCA1/2* mutated stage 242 III/IV ovarian cancers show significantly longer PFS compared to germline BRCA1/2 wildtype 243 stage III/IV ovarian cancers (aHR, 0.32; 95%CI, 0.14-0.72; p = 0.006) (Figure 6). In addition, 244 germline BRCA1/2 mutation was significantly associated with OS in stage III/IV ovarian cancer 245 (aHR, 0.12; 95%CI, 0.02-0.59; p = 0.009).

246

#### 247 **4. Discussion**

Our multicenter collaborative prospective observational study revealed that the frequency of HRD in Japanese patients with ovarian cancer was 45.2% and that HRD was significantly associated with PFS and OS in advanced stage ovarian cancer.

251 In this study, we enrolled patients who were clinically diagnosed with ovarian cancer and could 252 provide tumor tissue sample after surgery. Compared to the real-world distribution of each histology based on the JSOG annual report<sup>22</sup>, the proportion of mucinous carcinoma and low-253 254 grade serous carcinoma was smaller in the JGOG3025 trial. This may be due to the difficulty of 255 preoperative diagnosis and tumor tissue sampling in mucinous and low-grade serous carcinomas. 256 HRD was significantly associated with prognosis in Stage III/IV ovarian cancer but not in Stage 257 I/II. The distribution of histologic types differed between Stage I/II and Stage III/IV, and the 258 proportion of high-grade serous carcinoma was higher in Stage III/IV than in Stage I/II. 259 Therefore, the frequency of BRCA1/2 mutations was also higher in Stage IIII/IV. It is well known that BRCA1/2 mutation is associated with platinum sensitivity in ovarian cancer<sup>23</sup>, and 260 261 BRCA1/2 status might affect the present results. On the other hand, we also found an association 262 between PFS and HRD in Stage III/IV clear cell carcinoma whish harbored less BRCA1/2 263 mutation. These results suggest that not only BRCA1/2 but also other HR-associated gene mutations are linked with platinum sensitivity in advanced-stage ovarian cancer<sup>24</sup>. 264

Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer was approved by health insurance in January 2018 in Japan. The SOLO2 trial has shown that Olaparib treatment group has longer OS (median 51.7 months; 95%CI 41.5-59.1) than the placebo group (median 38.8 months; 95%CI 31.4-48.6) (HR 0.74; 95%CI 0.54-1.00; p = 0.054) although 38% of the

placebo group received subsequent PARP inhibitor therapy<sup>25</sup>. In addition, niraparib for platinumsensitive relapsed or HRD ovarian cancers was also approved by health insurance in September
2020. Therefore, it is necessary to verify whether there is a difference in the rate of PARP
inhibitor administration between HRD and non-HRD groups.

273 In this study, HRD was defined as the presence of at least one HR-related gene mutations. In 274 clinical practice, Myriad myChoice diagnostic system is now covered by health insurance in 275 Japan and is the standard method for assessing genomic instability (GI) score calculated by genomic loss of heterozygosity (LOH)<sup>26</sup>, telomeric allelic imbalance (TAI)<sup>27</sup>, and large-scale 276 state transition (LST)<sup>28</sup>. Recently, the assessment of HRD based on mutational signature is also 277 proposed<sup>29, 30</sup>. However, the two methods reflect the genomic scar caused HRD and do not 278 279 indicate whether the current tumor is HRD or not. On the other hand, HR-associated gene 280 mutation is one of the etiologies of HRD. It is well known that BRCA1/2 mutations are 281 significantly correlated with GI score and significantly associated with clinical outcome in 282 ovarian cancer. However, the clinical significance of HR-associated genes except BRCA1/2 283 remains unclear. Recently, PAOLA-1 subsequent analysis demonstrated that HR-associated gene 284 mutation (excluding BRCA1/2 mutation) was not predictive of PFS benefit with maintenance 285 olaparib in combination with bevacizumab, compared with bevacizumab alone, in PAOLA-1 286 trial and that only five genes (BLM, BRIP1, RAD51C, PALB2, and RAD51D) had a median GI 287 score  $\geq 42$ . Further multi-omics data analysis should be needed to the clinical impact of each 288 HR-associated gene mutation in ovarian cancer.

Our study has several limitations. The HR-associated mutations may be monoallelic, without any alterations in the opposite allele. Although tumors with MSI-High or POLE mutations were excluded from HRD, other HR-associated mutations may also not contribute to tumorigenesis.

292	As correlation between GI score and HR-associated mutations has not been analyzed, the HRD
293	status in each tumor has not been fully verified. In addition, the target sequencing cannot pick up
294	tumors with epigenetic alterations (such as hypermethylation in promoter region in BRCA1 or
295	<i>RAD51C</i> ).
296	In conclusion, HRD was detected in not only high-grade serous histologic type but also other
297	histologic types, and HRD status may be useful to provide an effective treatment option for
298	patients with ovarian cancer.
299	
300	Acknowledgments
301	The authors wish to thank all members of the Japanese Gynecologic Oncology Group. We
302	appreciate all women who participated in this study and their families, the staff of Translational
303	Research Center for Medical Innovation (TRI; the data and statistical analysis center for
304	JGOG3025), and the participating JGOG member institutions.

305

# 306 **Disclosure statement:**

307 The authors except KY declare that they have no conflicts of interest. Although KY received308 only lecture fees from Astrazeneca, he has no other conflicts of interest to declare.

309

#### 310 Funding Information

311 This study was partially funded by AstraZeneca Externally Sponsored Research.

312

#### 313 **Ethics Statement**

1. Cohort name: Japanese patients with ovarian cancer cohort (JGOG3025)

- 315 2. Non-abbreviated, full name of Ethics Committee / Institutional Review Board (IRB) for the
- 316 cohort: The Ethics Committee of the Japanese Gynecologic Oncology Group and Niigata
- 317 University
- 318 3. Decision made by ethics oversight body: approved (No. JGOG3025 in the Ethics Committee
- 319 of JGOG and No. 2006-0006 in Niigata University)
- 320 4. Informed Consent: All patients provided written informed consent.
- 321 5. Registry and the Registration No. of the study/trial: NCT03159572 (ClinicalTrials.gov);
- 322 UMIN 000026303 (UMIN-CTR)
- 323 6. Animal Studies: N/A
- 324
- 325 **References**
- Vergote I, Gonzalez-Martin A, Ray-Coquard I, et al. European experts consensus:
   BRCA/homologous recombination deficiency testing in first-line ovarian cancer. *Ann Oncol.* 2022; 33: 276-287.
- Lord CJ, Ashworth A. The DNA damage response and cancer therapy. *Nature*. 2012;
  481: 287-294.
- 331 3 Pierson WE, Peters PN, Chang MT, et al. An integrated molecular profile of
  and endometrioid ovarian cancer. *Gynecol Oncol.* 2020; 157: 55-61.
- Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in PlatinumSensitive, Recurrent Ovarian Cancer. *N Engl J Med.* 2016; 375: 2154-2164.
- 335 5 Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus 336 niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-

337 AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. *Lancet Oncol.* 

338 2019; 20: 1409-1419.

- Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line
  Maintenance in Ovarian Cancer. *N Engl J Med.* 2019; 381: 2416-2428.
- 341 7 Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma.
   342 *Nature*. 2011; 474: 609-615.
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous
  Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. *Cancer Discov.* 2015; 5: 1137-1154.
- Komiyama S, Katabuchi H, Mikami M, et al. Japan Society of Gynecologic Oncology
  guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer
  and fallopian tube cancer. *Int J Clin Oncol.* 2016; 21: 435-446.
- Tokunaga H, Mikami M, Nagase S, et al. The 2020 Japan Society of Gynecologic
  Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and
  primary peritoneal cancer. *J Gynecol Oncol.* 2021; 32: e49.
- Xu C, Gu X, Padmanabhan R, et al. smCounter2: an accurate low-frequency variant
  caller for targeted sequencing data with unique molecular identifiers. *Bioinformatics*.
  2019; 35: 1299-1309.
- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants
  from high-throughput sequencing data. *Nucleic Acids Res.* 2010; 38: e164.
- Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and
  comprehensive analysis of somatic variants in cancer. *Genome Res.* 2018; 28: 1747-1756.

- 359 14 Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum
  360 quantified from variation in 141,456 humans. *Nature*. 2020; 581: 434-443.
- 361 15 Genomes Project C, Auton A, Brooks LD, et al. A global reference for human genetic
  362 variation. *Nature*. 2015; 526: 68-74.
- 36316Karczewski KJ, Weisburd B, Thomas B, et al. The ExAC browser: displaying reference
- data information from over 60 000 exomes. *Nucleic Acids Res.* 2017; 45: D840-D845.
- Fu W, O'Connor TD, Jun G, et al. Analysis of 6,515 exomes reveals the recent origin of
  most human protein-coding variants. *Nature*. 2013; 493: 216-220.
- Tadaka S, Saigusa D, Motoike IN, et al. jMorp: Japanese Multi Omics Reference Panel.
   *Nucleic Acids Res.* 2018; 46: D551-D557.
- Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMGAMP Guidelines. *Am J Hum Genet*. 2017; 100: 267-280.
- Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In
  Cancer. *Nucleic Acids Res.* 2019; 47: D941-D947.
- Zhang J, Bajari R, Andric D, et al. The International Cancer Genome Consortium Data
  Portal. *Nat Biotechnol.* 2019; 37: 367-369.
- Yoshino K, Kurita T, Takahashi F, Nagase S, Board members of the Committee on
  Gynecologic Oncology of the Japan Society of O, Gynecology. Annual report of the
  committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology:
  Annual patient report for 2019 and annual treatment report for 2014. *J Obstet Gynaecol Res.* 2022; 48: 1570-1579.

- 380 23 Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with
  381 survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian
  382 cancer. *JAMA*. 2011; 306: 1557-1565.
- 38324Takamatsu S, Brown JB, Yamaguchi K, et al. Utility of Homologous Recombination
- 384 Deficiency Biomarkers Across Cancer Types. *JCO Precis Oncol.* 2022; 6: e2200085.
- Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in
  patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation
  (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-
- 388 controlled, phase 3 trial. *Lancet Oncol.* 2021; 22: 620-631.
- Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity
   predict homologous recombination repair defects in epithelial ovarian cancer. *Br J Cancer.* 2012; 107: 1776-1782.
- Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective
  DNA repair and sensitivity to DNA-damaging agents. *Cancer Discov.* 2012; 2: 366-375.
- Popova T, Manie E, Rieunier G, et al. Ploidy and large-scale genomic instability
  consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. *Cancer Res.* 2012; 72: 5454-5462.
- Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in
  human cancer. *Nature*. 2013; 500: 415-421.
- 399 30 Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker
- 400 testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian
  401 cancer. *Ann Oncol.* 2020.

#### Table 1. Clinicopathological characteristics of FAS

	FAS (n = 701)
Age	
< 65 years	474 (67.6%)
$\geq 65$ years	227 (32.4%)
FIGO stage	
I/II	332 (47.4%)
III/IV	362 (51.6%)
Unknown	7 (1.0%)
Histologic type	
High-grade serous carcinoma	298 (42.5%)
Clear cell carcinoma	189 (27.0%)
Endometrioid carcinoma	135 (19.3%)
Mucinous carcinoma	12 (1.7%)
Low-grade serous carcinoma	3 (0.4%)
Others	64 (9.1%)
Surgery	
Complete	520 (74.2%)
Optimal (<1cm)	75 (10.7%)
Not optimal (≥1cm)	104 (14.8%)
Unknown	2 (0.3%)
Neoadjuvant chemotherapy	
Yes	152 (21.7%)
No	549 (78.3%)
Adjuvant chemotherapy	
Yes	612 (87.3%)
No	89 (12.7%)

# **Table 2. The frequency of HRD by histologic type**

Histology	Ν	HRD	BRCA1	BRCA2	BRCA1+2
High-grade serous carcinoma	298	154 (51.7%)	52 (17.4%)	33 (11.1%)	2 (0.7%)
Clear cell carcinoma	189	81 (42.9%)	6 (3.2%)	2 (1.1%)	0 (0%)
Endometrioid carcinoma	135	49 (36.3%)	6 (4.4%)	16 (11.9%)	3 (2.2%)
Mucinous carcinoma	12	3 (25.0%)	0 (0%)	0 (0%)	0 (0%)
Low-grade serous carcinoma	3	3 (100%)	0 (0%)	0 (0%)	0 (0%)
Others	64	27 (42.2%)	5 (7.8%)	3 (4.7%)	2 (3.1%)




Figure 1. A schema of JGOG 3025 trial.





Figure 2. Patients disposition



HRD 45.2% (95%Cl, 41.5-49.0%)

Figure 3. Frequency of HRD in Japanese patients with ovarian cancer




Figure 4. Association between PFS and HRD in Japanese patients with ovarian cancer




Figure 5. Association between OS and HRD in Japanese patients with ovarian cancer




Figure 6. Association of germline BRCA1/2 mutation with PFS and OS in stage III/IV ovarian cancer